All In MedTech

Device Trial Radar · NCT07880756

Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness

A Prospective, Multicenter, Evaluator-Blinded, Randomized, No-treatment-controlled Study to Evaluate the Safety and Effectiveness of NOA HYDRATION in the Improvement of Skin Quality Including Attributes Such as Skin Smoothness

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
AbbVieNot on our public-company list
Sponsor type
Industry
First posted
Oct 19, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial skin quality, including attributes such as skin smoothness, can be affected by intrinsic aging and environmental factors. The goal of this study is to evaluate the safety and effectiveness of NOA HYDRATION, an injectable gel designed for intradermal placement, in improving facial skin quality including attributes such as skin smoothness in Chinese adults. NOA HYDRATION is an investigational device being developed for improvement of facial skin quality including attributes such as skin smoothness. Participants are placed into one of two groups - a treatment group or a control group (no-treatment control). There is a 1 in 3 chance that participants will be assigned to the control group. Approximately 150 adult participants seeking improvement in skin quality including attributes such as skin smoothness will be enrolled at approximately 7 sites in China. Participants in the treatment group will receive intradermal injections of NOA HYDRATION to the facial area (excluding forehead, nose, lips, and periocular areas) on Day 1. An optional touch-up treatment may be given at Day 31. The treatment group will be followed for 12 months after the last treatment. Participants in the control group will receive no treatment for 2 months, then may receive optional treatment and will be followed for 9 months after treatment. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a clinic. The effects of the treatment will be checked by medical assessments, questionnaires, photography, and checking for side effects.

Conditions

  • Skin Quality

Interventions

  • NOA HYDRATIONDevice

    Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Responder Status Based on Evaluating Investigator (EI)'s Live Assessment of Allergan Cheek Smoothness Scale (ACSS)Time frame: Month 2

2 more outcomes with a free account

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital /ID# 281119

    Beijing, Beijing Municipality, China · Recruiting

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.